EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Obesity phenotypes and atherogenic dyslipidemias

Hun Jee Choe, Talal Almas, Ian J Neeland iD, Soo Lim, Jean-Pierre Després

European Journal of Clinical Investigation · 2026-01 · 56 (1)

DOI: 10.1111/eci.70151 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 21.11.2025. Verfasst von Hun Jee Choe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea. Hauptthemen laut MEDLINE: Dyslipidemias, Obesity, Atherosclerosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 241 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity and atherogenic dyslipidemias are interrelated disorders that substantially contribute to the development of atherosclerotic cardiovascular disease (ASCVD) and the broader cardiovascular–kidney–metabolic (CKM) syndrome. The heterogeneity of obesity, particularly the role of visceral, ectopic and dysfunctional adipose tissue, drives the dyslipidemia phenotype characterized by hypertriglyceridemia, reduced high‐density lipoprotein cholesterol and elevated apolipoprotein B–containing lipoproteins.

Methods

We review the epidemiological studies, imaging analyses, genetic data and clinical trial evidence linking obesity phenotypes with dyslipidemias and cardiovascular outcomes. We further evaluated lifestyle, pharmacological and surgical strategies targeting obesity‐related lipid abnormalities.

Results

Visceral and ectopic fat accumulation, rather than body mass index alone, strongly predicts adverse lipid patterns, insulin resistance and cardiovascular events. Atherogenic dyslipidemias contribute to substantial residual ASCVD risk despite low‐density lipoprotein cholesterol lowering. Lifestyle interventions—including diet modification, physical activity and improved cardiorespiratory fitness—demonstrate favourable effects on lipid metabolism independent of weight loss. Traditional pharmacotherapies such as statins, fibrates and omega‐3 fatty acids offer partial benefits, while novel incretin‐based agents and dual or triple receptor agonists provide robust weight loss and metabolic improvements. Metabolic and bariatric surgery remains an effective approach for sustained weight reduction and remission of dyslipidemias in the appropriate patient and is increasingly integrated with pharmacotherapy.

Conclusions

Atherogenic dyslipidemias are a hallmark of high‐risk obesity phenotypes and a major contributor to ASCVD within the CKM framework. Precision medicine approaches that incorporate obesity phenotyping, targeted treatment strategies and population‐level interventions are needed to reduce the burden of dyslipidemias and their cardiovascular sequelae.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasObesityAtherosclerosisHumansPhenotypeBariatric SurgeryHypertriglyceridemiaLife StyleCholesterol, HDL

Stichwörter der Autor:innen

atherosclerosiscardiovascular diseasedyslipidemiaobesity

Substanzen

Cholesterol, HDL

Autor:innen und Institutionen

  • Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea.
  • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
  • Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec, Québec, Canada.
  • VITAM - Centre de Recherche en Santé Durable, Centre Intégré Universitaire de Santé et de Services Sociaux de la Capitale-Nationale, Québec, Québec, Canada.

ORCID-Profile: Ian J Neeland

Zitieren

APA

Choe, H. J., Almas, T., Neeland, I. J., Lim, S., & Després, J. P. (2026). Obesity phenotypes and atherogenic dyslipidemias. European Journal of Clinical Investigation, 56(1). https://doi.org/10.1111/eci.70151

Vancouver

Choe HJ, Almas T, Neeland IJ, Lim S, Després JP. Obesity phenotypes and atherogenic dyslipidemias. European Journal of Clinical Investigation. 2026;56(1). doi:10.1111/eci.70151

BibTeX
@article{Choe2026,
  author = {Choe, Hun Jee and Almas, Talal and Neeland, Ian J and Lim, Soo and Després, Jean-Pierre},
  title = {Obesity phenotypes and atherogenic dyslipidemias},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  volume = {56},
  number = {1},
  doi = {10.1111/eci.70151}
}
Kostenlos starten →